Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3537021 for prevention of chemotherapy-induced nausea and vomiting in adults with cancer
2025-522204-24-00Phase 2Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing LY3537021 plus antiemetic standard of care with Placebo plus antiemetic standard of care (2 arms). Primary endpoint: Complete response in delayed phase of chemotherapy-induced nausea and vomiting. Planned start Jun 2026; status: authorised.
02
Drugs
LY3537021
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2025-522204-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522204-24-00.